European Journal of CancerRyden A, Lawrance R, Papadakis K, et al. Patient-reported symptom response and impact of treatment with AZD9291 for advanced non-small-cell lung cancer [abstract no. 3030 plus poster]. In: European Cancer Congress; 2015....
Preliminary AZD9291 Western and Asian clinical pharmacokinetics (PK) in patients (pts) and healthy volunteers (HV):implications for formulation,dose and dosing frequency in pivotal clinical studies[abstract no.464P plus poster]. PLANCHARD D,DICKINSON PA,BROWN KH,et al. Annals of Oncology . 2014...
AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from phase II studies [abstract no. 3083 plus poster]. In: European Cancer Congress; 2015.Ahn, M., Tsai, C., Yang, J., Shepherd, F., Satouchi, M., Kim, D. et...
Thress KS, Yang JC-H, Ahn M-J, et al. Levels of EGFR T790M in plasma DNA as a predictive biomarker for response to AZD9291, a mutant-selective EGFR kinase inhibitor [abstract no. 1270P plus poster]. Ann Oncol 2014;25(Suppl 4):iv446-7....